Healthcare provider profile · identity verified

Eugene Matthew Tan, MD

Internal Medicine · WHEAT RIDGE, CO · NPI 1962848663

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	248	91
Levothyroxine Sodium	Levothyroxine Sodium	186	60
Duloxetine Hcl	Duloxetine Hcl	153	70
Lisinopril	Lisinopril	149	53
Amlodipine Besylate	Amlodipine Besylate	133	51
Rosuvastatin Calcium	Rosuvastatin Calcium	128	50
Losartan Potassium	Losartan Potassium	124	47
Albuterol Sulfate Hfa	Albuterol Sulfate	107	53
Omeprazole	Omeprazole	103	38
Furosemide	Furosemide	83	39
Pradaxa	Dabigatran Etexilate Mesylate	75	34
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	70	51
Simvastatin	Simvastatin	70	26
Tamsulosin Hcl	Tamsulosin Hcl	70	29
Trazodone Hcl	Trazodone Hcl	69	26
Metformin Hcl	Metformin Hcl	60	27
Metoprolol Tartrate	Metoprolol Tartrate	51	23
Prednisone	Prednisone	49	31
Metoprolol Succinate	Metoprolol Succinate	48	21
Pantoprazole Sodium	Pantoprazole Sodium	48	27
Gabapentin	Gabapentin	47	22
Triamcinolone Acetonide	Triamcinolone Acetonide	47	35
Metformin Hcl Er	Metformin Hcl	44	15
Fluoxetine Hcl	Fluoxetine Hcl	43	suppressed
Allopurinol	Allopurinol	41	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	15
Atenolol	Atenolol	38	12
Mirtazapine	Mirtazapine	37	15
Buspirone Hcl	Buspirone Hcl	36	13
Potassium Chloride	Potassium Chloride	35	14
Oxycodone Hcl	Oxycodone Hcl	34	11
Arexvy	Rsvpref3 Antigen/As01e/Pf	33	33
Topiramate	Topiramate	33	14
Hydrochlorothiazide	Hydrochlorothiazide	30	11
Donepezil Hcl	Donepezil Hcl	28	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	27	14
Tramadol Hcl	Tramadol Hcl	27	12
Spironolactone	Spironolactone	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	18
Famotidine	Famotidine	23	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	22	22
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Lorazepam	Lorazepam	21	15
Cefuroxime	Cefuroxime Axetil	20	17
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	17
Humulin N	Insulin Nph Human Isophane	20	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	20	19
Acyclovir	Acyclovir	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Glipizide	Glipizide	19	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	18	18
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Jardiance	Empagliflozin	16	suppressed
Naloxone Hcl	Naloxone Hcl	16	15
Ondansetron Odt	Ondansetron	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	12
Alvesco	Ciclesonide	15	suppressed
Ciclopirox	Ciclopirox	15	suppressed
Colchicine	Colchicine	15	suppressed
Estradiol	Estradiol	15	suppressed
Finasteride	Finasteride	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Methenamine Hippurate	Methenamine Hippurate	15	suppressed
Ozempic	Semaglutide	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	14	14
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Sertraline Hcl	Sertraline Hcl	14	suppressed
Fluconazole	Fluconazole	13	13
Propranolol Hcl	Propranolol Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Eliquis	Apixaban	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error